Predictive Oncology’s (POAI) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Predictive Oncology (NASDAQ:POAI) in a research note published on Friday, Marketbeat reports. HC Wainwright also issued estimates for Predictive Oncology’s Q4 2025 earnings at $0.06 EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.46 EPS.

Predictive Oncology Stock Down 7.2 %

POAI traded down $0.05 during mid-day trading on Friday, reaching $0.69. 145,775 shares of the company traded hands, compared to its average volume of 1,323,487. The stock has a market capitalization of $4.58 million, a P/E ratio of -0.23 and a beta of 1.14. Predictive Oncology has a 52-week low of $0.55 and a 52-week high of $3.76. The company’s fifty day moving average price is $0.75 and its 200-day moving average price is $1.07.

Predictive Oncology (NASDAQ:POAI) last issued its quarterly earnings results on Tuesday, August 13th. The medical instruments supplier reported ($0.68) earnings per share for the quarter. Predictive Oncology had a negative return on equity of 286.30% and a negative net margin of 1,012.32%. The business had revenue of $0.28 million for the quarter. As a group, sell-side analysts forecast that Predictive Oncology will post -2.03 earnings per share for the current fiscal year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.